Lyme Disease Pipeline 2025: In-depth Analysis and Emerging Therapies Report

Strategic Insights -

The Lyme disease pipeline is abuzz with activity as numerous companies work tirelessly to develop effective treatment therapies. According to a recent report by DelveInsight, the Lyme disease pipeline consists of 7+ key companies, with 7+ Lyme disease treatment therapies in various stages of clinical development. The report provides an in-depth analysis of the pipeline products, including their mechanism of action, clinical trials, and NDA approvals. Some of the key takeaways from the report include the growing number of companies developing novel Lyme disease treatment therapies, with emerging therapies such as BLB 400, FP-100, CT38, TP-05, and VLA15 expected to have a significant impact on the Lyme disease market in the coming years.

Key Takeaways:

  • 7+ key companies are working towards developing 7+ Lyme disease treatment therapies, including CyanVac, Flightpath Biosciences, Inc, Cortene Inc., Tarsus Pharmaceuticals, Inc, Valneva SE, and others.
  • Emerging therapies such as BLB 400, FP-100, CT38, TP-05, and VLA15 are in various stages of clinical development and are expected to have a significant impact on the Lyme disease market.
  • Valneva and Pfizer reported additional positive Phase II booster results for their Lyme disease vaccine candidate, VLA15, in September 2024.
  • In July 2024, Valneva and Pfizer announced that the primary vaccination series for their Phase III VALOR trial of the Lyme disease vaccine has been completed.
  • Tarsus announced encouraging topline results from Carpo, a Phase IIa Proof-of-Concept "Tick-Kill" trial assessing TP-05 (lotilaner) for Lyme disease prevention in February 2024.

Statistics:

  • 7+ companies are working on Lyme disease pipelines.
  • 7+ Lyme disease treatment therapies are in development.
  • BLB 400, FP-100, CT38, TP-05, and VLA15 are emerging therapies in various stages of clinical development.
  • Valneva and Pfizer reported positive Phase II booster results for VLA15 in September 2024.
  • Valneva and Pfizer completed the primary vaccination series for the Phase III VALOR trial in July 2024.
  • Tarsus announced encouraging topline results from Carpo in February 2024.

Sources:

  • DelveInsight's report: Lyme Disease Pipeline Insight, 2025
  • M2 PressWIRE - August 28, 2025 - Lyme Disease Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight
  • M2 Communications - M2 PressWIRE - August 28, 2025 - Lyme Disease Pipeline 2025: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight
  • DelveInsight's website - Lyme Disease Pipeline Report